News
Trontinemab’s Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback